Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Jerome Powell Attends Supreme Court Hearing on Trump Effort to Fire Fed Governor, Calling It Historic 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
